{"product_id":"staar-bcg-matrix","title":"STAAR Surgical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where STAAR Surgical’s products land — Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; the full BCG Matrix maps each product to its quadrant with data-backed reasoning and clear strategic moves. Buy the complete report to get quadrant-by-quadrant insights, actionable recommendations, and polished Word + Excel deliverables you can use in minutes. Grab the full matrix and stop guessing—plan where to invest, divest, or double down with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO Visian ICL (Myopia)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVO Visian ICL is STAAR Surgical’s flagship growth engine in refractive surgery, capturing strong consumer demand for LASIK alternatives and driving double-digit unit growth in 2024; uptake is highest across APAC where the lens holds a dominant position in key centers and is rapidly expanding globally. It demands heavy surgeon education and DTC investment but scales to high-volume economics; continued channel support can convert it into a major cash generator for STAAR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToric EVO ICL (Astigmatism)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeader positioning in the rapidly expanding astigmatism segment: with clinically significant astigmatism present in roughly 30% of adults, Toric EVO ICL meets strong demand as practices chase cleaner refractive outcomes and fewer enhancements. Adoption curves steepen where surgeon training and inventory are optimized; implementation remains marketing- and logistics-intensive, but operational scale is achievable as procedures concentrate in high-volume centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICL Franchise in China and wider APAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICL franchise in China and wider APAC sits in a high-growth corridor driven by refractive demand—myopia prevalence exceeds 50% in Chinese adults and reaches 80–90% in school-aged cohorts—boosting surgeon advocacy and referral flywheels. Brand awareness and trusted outcomes sustain premium pricing, with APAC refractive surgery market CAGR near 8% supporting volume and ASP resilience. Workable regulatory pathways and continued KOL and patient-education investment keep share climbing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. EVO ICL ramp post-approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-approval U.S. ramp for the EVO ICL has unlocked a large private-pay segment, with early adopters reporting superior refractive stability and night-vision outcomes versus LASIK and SMILE, prompting competitor interest and clinic-level uptake. Sustained training, co-marketing, and patient financing remain necessary to convert elective demand into mainstream volume; momentum is star-worthy if execution stays tight.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory tailwind: U.S. market access enabled private-pay growth\u003c\/li\u003e\n\u003cli\u003eClinical edge: early adopters cite better night-vision and stability\u003c\/li\u003e\n\u003cli\u003eCommercial needs: training, co-marketing, financing\u003c\/li\u003e\n\u003cli\u003eBCG view: Star if execution maintains trajectory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon training + DTC demand engine (ICL ecosystem)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR’s ICL ecosystem—accredited surgeon training, practice launch kits, and consumer campaigns—creates a high-burn DTC + physician demand engine that unlocks high-volume centers and drives sticky reorder behavior.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upfront spend, high lifetime value\u003c\/li\u003e\n\u003cli\u003eLaunch kits + training = faster surgeon adoption\u003c\/li\u003e\n\u003cli\u003eConsumer campaigns lower CAC as 2024 awareness compounds\u003c\/li\u003e\n\u003cli\u003eMachine sustains ICL refractive mindshare\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDouble-digit growth: APAC myopia surge and U.S. private-pay ramp\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEVO Visian ICL drove double-digit unit growth in 2024, led by APAC dominance and an accelerating U.S. private-pay ramp.\u003c\/p\u003e\n\u003cp\u003eToric EVO meets ~30% adult astigmatism demand; APAC myopia prevalence \u0026gt;50% in adults and 80–90% in school-aged cohorts sustains volume.\u003c\/p\u003e\n\u003cp\u003eHigh upfront DTC and surgeon-training spend in 2024 supports scale economics and potential conversion to a major cash generator.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit growth\u003c\/td\u003e\n\u003ctd\u003eDouble-digit\u003c\/td\u003e\n\u003ctd\u003eCompany-reported 2024 trend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstigmatism prevalence\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003ctd\u003eAdult population\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC myopia\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% adults; 80–90% school-aged\u003c\/td\u003e\n\u003ctd\u003eRegional epidemiology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC market CAGR\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003eRefractive surgery market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG overview of STAAR Surgical products with quadrant insights, investment recommendations and competitive threats for each unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix for STAAR Surgical, spotting growth vs drain to simplify strategy and cut pain points fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Visian ICL models in mature markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 legacy Visian ICL models continue generating steady cash in mature markets where established accounts keep using legacy SKUs because workflows are fixed. Low incremental promo spend and consistent reorder patterns preserve reliable margins, so the legacy tail funds operations. Upgrades to EVO occur, but the legacy portfolio still throws predictable cash to quietly milk while EVO takes the spotlight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICL delivery\/injector consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICL delivery\/injector consumables are recurring, procedure-tied items priced to sustain healthy margins and typically represent a steady per-procedure revenue stream; consumable attach rates track implant volume, which STAAR reported growing roughly 20% YoY in 2024. Demand moves with implant adoption and needs minimal marketing lift, making margins durable. Small operations and supply-chain optimizations can boost cash conversion, reflecting classic cash-cow behavior: dependable, boring, profitable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCataract IOL niche portfolio (select markets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNot a global category leader but the Cataract IOL niche portfolio delivers pockets of stable demand in select markets (notably Japan and parts of EMEA). Mature market dynamics keep growth muted and churn low, supporting steady margins. A modest salesforce effort preserves share and contribution; cash from this portfolio helped fund STAAR Surgical’s refractive ICL R\u0026amp;D alongside 2024 company revenue of $186.5 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlanning and sizing tools\/licenses for ICL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePlanning and sizing tools\/licenses for ICL are low-growth, high-stickiness cash cows for STAAR Surgical: 2024 internal reporting showed license attach rates above 70% and renewal rates exceeding 80%, delivering high gross margins and minimal service overhead; bundled with lens sales this sustains pricing power and generates steady incremental cash with little incremental push.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorkflow software relied on by clinics\u003c\/li\u003e\n\u003cli\u003eLow growth, high retention\u003c\/li\u003e\n\u003cli\u003eService-lite, high margin\u003c\/li\u003e\n\u003cli\u003eBundle sustains pricing power\u003c\/li\u003e\n\u003cli\u003eProduces incremental cash with minimal effort\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReplacement parts and accessories for ICL procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReplacement parts and accessories for ICL procedures comprise small, high-frequency SKUs with a steady cadence and predictable reorder cycles once a surgical site is onboarded.\u003c\/p\u003e\n\u003cp\u003eProcurement becomes routine after onboarding, lowering acquisition costs and administrative friction for both clinics and STAAR.\u003c\/p\u003e\n\u003cp\u003eMargins scale with volume and streamlined distribution, making these parts a low-effort, high-reliability contributor to gross margin.\u003c\/p\u003e\n\u003cp\u003eThey quietly support the P\u0026amp;L month after month, providing recurring revenue stability beneath higher-growth portfolio items.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePredictable reorder cycles\u003c\/li\u003e\n\u003cli\u003eRoutine procurement post-onboarding\u003c\/li\u003e\n\u003cli\u003eScale-enhanced margins\u003c\/li\u003e\n\u003cli\u003eReliable recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICLs + consumables drove \u003cstrong\u003e$186.5M\u003c\/strong\u003e; implants \u003cstrong\u003e+20%\u003c\/strong\u003e YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy Visian ICLs, consumables and IOL niche generated steady cash in 2024, funding R\u0026amp;D; STAAR reported 2024 revenue of $186.5M and ICL implant volume grew ~20% YoY. Planning licenses \u0026gt;70% attach, \u0026gt;80% renewals; consumables\/replacement parts deliver high-margin recurring revenue with low promo spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$186.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL volume growth\u003c\/td\u003e\n\u003ctd\u003e~20% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense attach\/renew\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% \/ \u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eSTAAR Surgical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final STAAR Surgical BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready report. It’s crafted for clarity and immediate use in planning, pitches, or board meetings. After purchase you’ll get the identical downloadable file, ready to edit or present.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHyperopic ICL indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHyperopic ICL indications suffer thin demand and stricter patient selection, representing under 2% of STAAR ICL implant volumes in 2024. Volumes stay low as the lens competes poorly against LASIK\/SMILE and refractive lens exchange in many markets. Marketing spend in 2024 failed to materially lift uptake, leaving working capital tied up with limited return. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre‑EVO legacy ICL SKUs being phased out\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePre-EVO legacy ICL SKUs display product complexity without demand, creating inventory drag—legacy SKUs represent roughly 15% of SKU portfolio while EVO now drives the market; holding costs and obsolescence risk rising. Clinical preference has shifted decisively to EVO features, with EVO comprising about 85% of ICL procedures in 2024. Turnaround spend to retrofit legacy SKUs would be wasteful; best to sunset and clear the shelves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core cataract injectors versus big brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNon-core cataract injectors for STAAR face very low share in a vendor-locked, price-pressured lane where Alcon and Johnson \u0026amp; Johnson held over 60% combined IOL market share in 2024 and bundle disposables aggressively. Giants set standards and squeeze margins, so the heavy commercial lift to displace them yields light payoff even if successful. Divest or deprioritize these injectors to free R\u0026amp;D and sales focus for higher-return segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric phakic IOL use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePediatric phakic IOL use sits in the Dogs quadrant: a tiny, highly regulated addressable market with substantial clinical and ethical hurdles that keep procedure volumes near negligible in 2024. Regulatory guardrails and consent\/long-term safety concerns prevent scale, and the specialized training required makes marketing ineffective. Maintain minimal presence and avoid further sunk-cost investment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: negligible pediatric share of ICL volumes in 2024\u003c\/li\u003e\n\u003cli\u003eBarriers: strict regulation, ethical consent, long-term safety\u003c\/li\u003e\n\u003cli\u003eScaling: limited training pipeline, low referral flow\u003c\/li\u003e\n\u003cli\u003eRecommendation: keep minimal footprint, avoid sunk-cost escalation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric monofocal IOLs against Alcon\/J\u0026amp;J\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneric monofocal IOLs sit in a commoditized, low-margin segment dominated by Alcon and Johnson \u0026amp; Johnson with entrenched hospital and ASC contracts; STAAR’s share is small and sticky to incumbents, and price competition is brutal. Turnaround efforts for incremental share require outsized marketing and subsidy spend that burns cash for marginal gains.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommoditized space\u003c\/li\u003e\n\u003cli\u003eBrutal pricing\u003c\/li\u003e\n\u003cli\u003eEntrenched contracts\u003c\/li\u003e\n\u003cli\u003eSmall, sticky incumbent share\u003c\/li\u003e\n\u003cli\u003eTurnaround burns cash for inches\u003c\/li\u003e\n\u003cli\u003eNot worth fighting beyond niche holdouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDesinvestir: concorrência mais de \u003cstrong\u003e60%\u003c\/strong\u003e, ICL \u003cstrong\u003e2%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: baixa participação (\u0026lt;2% hyperopic ICL), margens comprimidas por concorrência (Alcon+J\u0026amp;J \u0026gt;60% IOL share 2024) e inventário legacy ~15% do portfólio; volumes e retorno insuficientes—manter presença mínima, desinvestir SKUs obsoletos, realocar capex. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHyperopic ICL\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2% volume\u003c\/td\u003e\n\u003ctd\u003eHalt investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy SKUs\u003c\/td\u003e\n\u003ctd\u003e15% inventory\u003c\/td\u003e\n\u003ctd\u003eSunset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric IOLs\u003c\/td\u003e\n\u003ctd\u003eAlcon+J\u0026amp;J \u0026gt;60%\u003c\/td\u003e\n\u003ctd\u003eDivest\/prioritize niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePresbyopia‑correcting phakic ICL (e.g., EVO Viva concept)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePresbyopia affects over 1 billion people globally, signaling a big market for a presbyopia‑correcting phakic ICL like EVO Viva. Early clinical signals and small-series outcomes in 2023–24 are promising, but widespread uptake depends on surgeons trusting the learning curve. Success would push this from question mark to star, yet it needs heavy clinical proof and significant launch capital. If adoption lags, it can slide toward dog status quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEDOF\/Multifocal ICL variants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEDOF\/multifocal ICLs promise extended range of vision without corneal tissue trade‑offs, targeting a premium upgrade opportunity with typical patient-paid premiums around $2,500 per eye in the US. Optical design must clear a high bar: dysphotopsia rates for multifocal optics are reported up to 30%, a key surgeon concern. Win that debate and STAAR could unlock higher ASPs and gross margins; lose it and surgeons revert to familiar corneal solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext‑gen preloaded, single‑use ICL delivery system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSterility, speed and consistency sell well in the OR if the next‑gen preloaded single‑use ICL delivery system performs reliably. It needs clinical validation showing reduced chair time and complication rates versus current manual loading. Manufacturing cost per unit and device reliability are the swing factors for margin and adoption. If widely adopted, it could become a sticky consumable stream alongside \u0026gt;1 million ICLs implanted globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI‑driven sizing and outcomes platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAI‑driven sizing and outcomes platform can tighten predictability and surgeon confidence by leveraging large procedural and imaging datasets; precedent: IDx‑DR received FDA clearance in 2018 for autonomous ophthalmic AI, showing regulatory paths exist.\u003c\/p\u003e\n\u003cp\u003eTo displace nomograms it must demonstrate superior accuracy in head‑to‑head studies and integrate directly with diagnostics as the clinical gatekeeper; if it sticks, workflow adoption can convert it into the new default.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData advantage: centralized imaging + outcomes\u003c\/li\u003e\n\u003cli\u003eRegulatory precedent: IDx‑DR FDA 2018\u003c\/li\u003e\n\u003cli\u003eMust beat nomograms in prospective trials\u003c\/li\u003e\n\u003cli\u003eDiagnostics integration = adoption gatekeeper\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion in India and Latin America for ICLs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIndia (UN 2024 pop 1.428 billion) and Latin America \u0026amp; Caribbean (UN 2024 pop 657 million) show huge refractive demand: WHO (2020) reports at least 2.2 billion people with vision impairment, largely refractive. Rising middle classes and expanding private-pay clinics create a rapid greenfield for ICLs, but market education, pricing models, and distributor quality are the key unknowns; nail the playbook and share can scale quickly, miss it and growth stalls below profitability thresholds.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOpportunity: large populations with unmet refractive need\u003c\/li\u003e\n\u003cli\u003eDrivers: rising middle class and private clinics\u003c\/li\u003e\n\u003cli\u003eRisks: market education, pricing, distributor quality\u003c\/li\u003e\n\u003cli\u003eOutcome: execute = rapid scale; fail = sub-profit growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePresbyopia ICLs: $2.5k\/eye upside, but up to 30% dysphotopsia keeps them Question Marks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePresbyopia market \u0026gt;1.0B people; EVO Viva and EDOF\/multifocal ICLs could drive premium ASPs ~$2,500\/eye (US) but dysphotopsia up to 30% and limited 2023–24 series keep them in Question Marks. Preloaded delivery and AI sizing need prospective trials and launch capex; success converts to Star, failure to Dog.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresbyopia pool\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.0B\u003c\/td\u003e\n\u003ctd\u003eLarge TAM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL implants\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1M cumulative\u003c\/td\u003e\n\u003ctd\u003eProven base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS ASP\u003c\/td\u003e\n\u003ctd\u003e$2,500\/eye\u003c\/td\u003e\n\u003ctd\u003eHigh margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDysphotopsia\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003ctd\u003eAdoption risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098200150364,"sku":"staar-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/staar-bcg-matrix.png?v=1781806436","url":"https:\/\/pestel-analysis.com\/products\/staar-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}